TALEN

TALEN2-tp53

ID

ZDB-TALEN-181205-1

Name

TALEN2-tp53

Previous Names

None

Target

tp53 (1)

Target Sequence 1

5' - CTCTGTCCGTCAGGT - 3'

Target Sequence 2

5' - AGTTACAGGAGGAGC - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
fb105	tp53

Expression

Gene expression in Wild Types + TALEN2-tp53

No data available

Phenotype

Phenotype resulting from TALEN2-tp53

No data available

Phenotype of all Fish created by or utilizing TALEN2-tp53

Phenotype	Fish	Conditions	Figures
apoptotic process occurrence, ameliorated	tp53^fb105/fb105	gamma ray	Fig. 1-S1 from Ignatius et al., 2018
whole organism ab11-tp53 labeling absent, abnormal	tp53^fb105/fb105	standard conditions	Fig. 1-S1 from Ignatius et al., 2018
whole organism neurofibrosarcoma increased amount, abnormal	tp53^fb105/fb105	standard conditions	Fig. 1 from Ignatius et al., 2018
vasculature neoplastic, abnormal	tp53^fb105/fb105	standard conditions	Fig. 1 from Ignatius et al., 2018
germ line cell neoplastic, abnormal	tp53^fb105/fb105	standard conditions	Fig. 1 from Ignatius et al., 2018
whole organism neoplasm increased amount, abnormal	tp53^fb105/fb105	standard conditions	Fig. 1 from Ignatius et al., 2018
whole organism sarcoma increased amount, abnormal	tp53^fb105/fb105	standard conditions	Fig. 1 from Ignatius et al., 2018
whole organism Non-Lymphoid leukaemias increased amount, abnormal	tp53^fb105/fb105	standard conditions	Fig. 1 from Ignatius et al., 2018
interrenal gland nucleus low brightness, abnormal	tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
interrenal gland neuroblastoma neoplastic, metastatic, abnormal	tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
interrenal gland neuroblastoma increased size, abnormal	tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: olaparib, chemical treatment by environment: temozolomide	Fig. 3 from Hayes et al., 2025
interrenal gland neuroblastoma increased amount, abnormal	tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
interrenal gland neuroblastoma increased size, abnormal	tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation	Fig. 3 from Hayes et al., 2025
interrenal gland cell cycle G2/M phase transition increased occurrence, abnormal	atm^zf4268/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 4 from Hayes et al., 2025
interrenal gland neuroblastoma neoplastic, metastatic, exacerbated	atm^zf4268/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
interrenal gland cell cycle G1/S phase transition increased occurrence, abnormal	atm^zf4268/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 4 from Hayes et al., 2025
heart neuroblastoma ab7-h2afx labeling increased amount, abnormal	atm^{zf4268/zf4268}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
olfactory pit neuroblastoma ab7-h2afx labeling increased amount, abnormal	atm^{zf4268/zf4268}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
gill neuroblastoma ab7-h2afx labeling increased amount, abnormal	atm^{zf4268/zf4268}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
interrenal gland nucleus low brightness, exacerbated	atm^{zf4268/zf4268}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
interrenal gland neuroblastoma neoplastic, metastatic, exacerbated	atm^{zf4268/zf4268}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
liver neuroblastoma ab7-h2afx labeling increased amount, abnormal	atm^{zf4268/zf4268}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
interrenal gland nucleus Ab1-pcna labeling increased amount, abnormal	atm^{zf4268/zf4268}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
interrenal gland nucleus ab7-h2afx labeling increased amount, abnormal	atm^{zf4268/zf4268}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
interrenal gland neuroblastoma ab7-h2afx labeling amount, ameliorated	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: ceralasertib, chemical treatment by environment: olaparib	Fig. 6 from Hayes et al., 2025
interrenal gland neuroblastoma EGFP expression increased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: olaparib	Fig. 6 from Hayes et al., 2025
interrenal gland cell cycle G2/M phase transition increased occurrence, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 4 from Hayes et al., 2025
interrenal gland neuroblastoma ab4-chek1 labeling decreased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: ceralasertib, chemical treatment by environment: olaparib	Fig. 6 from Hayes et al., 2025
interrenal gland neuroblastoma ab7-h2afx labeling decreased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: olaparib	Fig. 6 from Hayes et al., 2025
interrenal gland neuroblastoma aurka expression increased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 4 from Hayes et al., 2025
interrenal gland neuroblastoma ab7-h2afx labeling decreased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: ceralasertib	Fig. 6 from Hayes et al., 2025
interrenal gland neuroblastoma dnmt1 expression increased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 4 from Hayes et al., 2025
interrenal gland neuroblastoma neoplastic, metastatic, exacerbated	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
interrenal gland neuroblastoma ab4-chek1 labeling decreased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: ceralasertib	Fig. 6 from Hayes et al., 2025
interrenal gland neuroblastoma rrm2 expression increased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 4 from Hayes et al., 2025
interrenal gland neuroblastoma mad2l1 expression increased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 4 from Hayes et al., 2025
interrenal gland cell cycle G1/S phase transition increased occurrence, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 4 from Hayes et al., 2025
interrenal gland neuroblastoma EGFP expression amount, ameliorated	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: ceralasertib, chemical treatment by environment: olaparib	Fig. 6 from Hayes et al., 2025
interrenal gland neuroblastoma EGFP expression increased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: ceralasertib	Fig. 6 from Hayes et al., 2025
interrenal gland neuroblastoma EGFP expression increased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation	Fig. 6 from Hayes et al., 2025
interrenal gland neuroblastoma lig1 expression increased amount, abnormal	brca2^zf4267/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 4 from Hayes et al., 2025
interrenal gland neuroblastoma increased size, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation	Fig. 3 from Hayes et al., 2025
interrenal gland nucleus Ab1-pcna labeling decreased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: olaparib, chemical treatment by environment: temozolomide	Fig. 3 from Hayes et al., 2025
interrenal gland neuroblastoma neoplastic, metastatic, exacerbated	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
olfactory pit neuroblastoma EGFP expression increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
gill neuroblastoma Ab60-th labeling increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
liver neuroblastoma neoplastic, metastatic, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
interrenal gland nucleus low brightness, exacerbated	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
gill neuroblastoma neoplastic, metastatic, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
olfactory pit neuroblastoma Ab60-th labeling increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
gill neuroblastoma EGFP expression increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
olfactory pit neuroblastoma neoplastic, metastatic, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
liver neuroblastoma Ab60-th labeling increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
interrenal gland nucleus Ab1-pcna labeling increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
interrenal gland neuroblastoma increased size, ameliorated	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: olaparib, chemical treatment by environment: temozolomide	Fig. 3 from Hayes et al., 2025
heart neuroblastoma EGFP expression increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
liver neuroblastoma EGFP expression increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
orbit neuroblastoma Ab60-th labeling increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
interrenal gland nucleus ab7-h2afx labeling increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
interrenal gland neuroblastoma ab11-casp3 labeling increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	cancer xenotransplantation, chemical treatment by environment: olaparib, chemical treatment by environment: temozolomide	Fig. 3 from Hayes et al., 2025
orbit neuroblastoma EGFP expression increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
heart neuroblastoma Ab60-th labeling increased amount, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
orbit neuroblastoma neoplastic, metastatic, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
heart neuroblastoma neoplastic, metastatic, abnormal	brca2^{zf4267/zf4267}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
interrenal gland neuroblastoma neoplastic, metastatic, exacerbated	palb2^zf4269/+; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
interrenal gland nucleus low brightness, exacerbated	palb2^{zf4269/zf4269}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
interrenal gland neuroblastoma neoplastic, metastatic, exacerbated	palb2^{zf4269/zf4269}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 2 from Hayes et al., 2025
interrenal gland nucleus Ab1-pcna labeling increased amount, abnormal	palb2^{zf4269/zf4269}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025
interrenal gland nucleus ab7-h2afx labeling increased amount, abnormal	palb2^{zf4269/zf4269}; tp53^fb105/fb105; zdf16Tg/zdf16Tg	standard conditions	Fig. 1 from Hayes et al., 2025

Citations